Chime Bio, flush with $190M, blueprints major biomanufacturing boost in China

After locking up a $125 million Series A in early 2020, China-based CDMO Chime Biologics has raised another $65 million to help build and kit out a second plant in Wuhan, China.

The $190 million investment will fuel an expansion over the next five years at its site in Wuhan, taking capacity there to 140,000 liters.